CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities

Members of the EGF-CFC (Cripto, FRL-1, Cryptic) protein family are increasingly recognized as key mediators of cell movement and cell differentiation during vertebrate embryogenesis. The founding member of this protein family, CRIPTO, is overexpressed in various human carcinomas. Yet, the biological role of CRIPTO in this setting remains unclear. Here, we find CRIPTO expression as especially high in a subgroup of primary prostate carcinomas with poorer outcome, wherein resides cancer cell clones with mesenchymal traits. Experimental studies in PCa models showed that one notable function of CRIPTO expression in prostate carcinoma cells may be to augment PI3K/AKT and FGFR1 signaling, which promotes epithelial-mesenchymal transition and sustains a mesenchymal state. In the observed signaling events, FGFR1 appears to function parallel to AKT, and the two pathways act cooperatively to enhance migratory, invasive and transformation properties specifically in the CRIPTO overexpressing cells. Collectively, these findings suggest a novel molecular network, involving CRIPTO, AKT, and FGFR signaling, in favor of the emergence of mesenchymal-like cancer cells during the development of aggressive prostate tumors.

[1]  Yi-Song Wang,et al.  CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. , 2014, The Journal of clinical investigation.

[2]  L. Norton,et al.  N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties , 2014, Oncogene.

[3]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[4]  H. Beltran,et al.  The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression , 2014, Front. Oncol..

[5]  M. Nieto Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells , 2013, Science.

[6]  Jixiang Ding,et al.  Cripto is required for mesoderm and endoderm cell allocation during mouse gastrulation. , 2013, Developmental biology.

[7]  Yan Li,et al.  NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. , 2013, The international journal of biochemistry & cell biology.

[8]  M. Hendrix,et al.  The significance of a Cripto-1-positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics , 2013, Cell cycle.

[9]  Fabrice Andre,et al.  Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. , 2013, Cancer discovery.

[10]  C. Dinney,et al.  Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting , 2013, PloS one.

[11]  Jing Yang,et al.  Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. , 2012, Cancer cell.

[12]  W. Vale,et al.  Cripto/GRP78 modulation of the TGF‐β pathway in development and oncogenesis , 2012, FEBS letters.

[13]  M. Knowles,et al.  FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated Mechanisms , 2012, PloS one.

[14]  C. Bianco,et al.  Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. , 2012, The American journal of pathology.

[15]  Biplab Bose,et al.  Human recombinant Cripto-1 increases doubling time and reduces proliferation of HeLa cells independent of pro-proliferation pathways. , 2012, Cancer letters.

[16]  John T. Wei,et al.  Beyond PSA: The Next Generation of Prostate Cancer Biomarkers , 2012, Science Translational Medicine.

[17]  A. Postigo,et al.  β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness , 2011, Proceedings of the National Academy of Sciences.

[18]  Manuel Hidalgo,et al.  Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. , 2011, Cell stem cell.

[19]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[20]  M. Hendrix,et al.  Expression and functional role of CRIPTO-1 in cutaneous melanoma , 2011, British Journal of Cancer.

[21]  M. Hendrix,et al.  Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells , 2011, The Prostate.

[22]  M. Henry,et al.  Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? , 2011, Nature Reviews Urology.

[23]  J. Shen,et al.  NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation , 2011, Oncogene.

[24]  Carlos L. Arteaga,et al.  Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.

[25]  Sarat Chandarlapaty,et al.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.

[26]  O. Kallioniemi,et al.  FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. , 2010, Cancer research.

[27]  Maria Cristina Rangel,et al.  Role of Cripto-1 in stem cell maintenance and malignant progression. , 2010, The American journal of pathology.

[28]  M. Hendrix,et al.  Cripto‐1 Is a Cell Surface Marker for a Tumorigenic, Undifferentiated Subpopulation in Human Embryonal Carcinoma Cells , 2010, Stem cells.

[29]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[30]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[31]  C. Bianco,et al.  Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1 , 2009, The Journal of cell biology.

[32]  J. C. Belmonte,et al.  Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways , 2009, Oncogene.

[33]  M. Klymkowsky,et al.  Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. , 2009, The American journal of pathology.

[34]  J. Trosko,et al.  Profiling Cancer Stem Cells in Androgen‐Responsive and Refractory Human Prostate Tumor Cell Lines , 2009, Annals of the New York Academy of Sciences.

[35]  D. Constam,et al.  Cripto Localizes Nodal at the Limiting Membrane of Early Endosomes , 2008, Science Signaling.

[36]  D. Constam,et al.  Cripto recruits Furin and PACE4 and controls Nodal trafficking during proteolytic maturation , 2008, The EMBO journal.

[37]  D. Brewer,et al.  Expression profiling of CD133+ and CD133— epithelial cells from human prostate , 2008, The Prostate.

[38]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[39]  A-P Lu,et al.  Positive association of up‐regulated Cripto‐1 and down‐regulated E‐cadherin with tumour progression and poor prognosis in gastric cancer , 2008, Histopathology.

[40]  Leif E. Peterson,et al.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. , 2007, Cancer cell.

[41]  W. Fischer,et al.  GRP78 and Cripto Form a Complex at the Cell Surface and Collaborate To Inhibit Transforming Growth Factor β Signaling and Enhance Cell Growth , 2007, Molecular and Cellular Biology.

[42]  C. Kennedy,et al.  Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[43]  S. Tabibzadeh,et al.  Lefty at the Crossroads of “Stemness” and Differentiative Events , 2006, Stem cells.

[44]  G. D'aiuto,et al.  Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer , 2006, Clinical Cancer Research.

[45]  J. Foidart,et al.  Regulation of vimentin by SIP1 in human epithelial breast tumor cells , 2006, Oncogene.

[46]  P. Karakiewicz,et al.  25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. , 2006, The Journal of urology.

[47]  M. Hendrix,et al.  Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness , 2006, Nature Medicine.

[48]  A. Ebert,et al.  Role of human cripto-1 in tumor angiogenesis. , 2005, Journal of the National Cancer Institute.

[49]  N. Normanno,et al.  Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV‐Cripto‐1 transgenic mice , 2004, Journal of cellular physiology.

[50]  N. Normanno,et al.  CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. , 2004, International journal of oncology.

[51]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[52]  N. Normanno,et al.  Cripto‐1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF‐7 breast cancer cells , 2004, Journal of cellular physiology.

[53]  Chenbei Chang,et al.  Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto. , 2003, Genes & development.

[54]  E. Adamson,et al.  Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells , 2003, The Journal of cell biology.

[55]  D. Kane,et al.  One-eyed pinhead regulates cell motility independent of Squint/Cyclops signaling. , 2003, Developmental biology.

[56]  N. Normanno,et al.  A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. , 2003, Cancer research.

[57]  F. Rosa Cripto, a Multifunctional Partner in Signaling: Molecular Forms and Activities , 2002, Science's STKE.

[58]  A. Ebert,et al.  Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. , 2001, Experimental cell research.

[59]  A. Ebert,et al.  Cripto-1 induces apoptosis in HC-11 mouse mammary epithelial cells , 2000, Cell Death and Differentiation.

[60]  S. Schwartz,et al.  A new human prostate carcinoma cell line, 22Rv1 , 1999, In Vitro Cellular & Developmental Biology - Animal.

[61]  A. Ebert,et al.  Cripto-1 Indirectly Stimulates the Tyrosine Phosphorylation oferb B-4 through a Novel Receptor* , 1999, The Journal of Biological Chemistry.

[62]  A. Wynshaw-Boris,et al.  Cripto is required for correct orientation of the anterior–posterior axis in the mouse embryo , 1998, Nature.

[63]  M. Kirschner,et al.  The identification of two novel ligands of the fgf receptor by a yeast screening method and their activity in xenopus development , 1995, Cell.

[64]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.

[65]  A. Simeone,et al.  The murine cripto gene: expression during mesoderm induction and early heart morphogenesis. , 1993, Development.

[66]  Silvana,et al.  Molecular characterization of a gene of the ‘EGF family’ expressed in undifferentiated human NTERA2 teratocarcinoma cells. , 1989, The EMBO journal.

[67]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[68]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[69]  Francesca Demichelis,et al.  Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. , 2011, Genome research.

[70]  N. Normanno,et al.  Cripto-1: an oncofetal gene with many faces. , 2005, Current topics in developmental biology.

[71]  Frank McCormick,et al.  Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. , 2004, Genes & development.

[72]  E. Okajima,et al.  Cripto expression in human urological tumors. , 1997, Cancer letters.